Skip to main content
Clinical Trials/NCT02096003
NCT02096003
Completed
Phase 2

Comparison of Intrathecal Hydromorphone and Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery

Icahn School of Medicine at Mount Sinai1 site in 1 country80 target enrollmentMay 2014

Overview

Phase
Phase 2
Intervention
Intrathecal morphine
Conditions
Pain
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
80
Locations
1
Primary Endpoint
Post Operative Fentanyl PCA Consumption
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The use of intrathecal opioids for analgesia in the setting of cesarean section has become standard obstetric anesthesia practice. Currently, two opioids are commonly used. These opioids are fentanyl and morphine (Duramorph). Intrathecal opioids are an excellent source of analgesia and act to reduce the stress response to surgery.

Currently, most obstetric anesthesiologists use intrathecal morphine for analgesia after cesarean delivery. Morphine provides excellent analgesia for cesarean section. However, use of this medication is associated with side effects such as pruritus and nausea and vomiting.

Recently, multiple obstetric anesthesia groups began to use intrathecal hydromorphone for cesarean delivery when morphine was unavailable. As groups began to use hydromorphone, retrospective data became available that demonstrated its safety and efficacy for use during cesarean section.

In order to fully elucidate the analgesic and side effect properties of hydromorphone for cesarean delivery, a prospective randomized, double blind study comparing morphine and hydromorphone is necessary. The investigators need to understand whether hydromorphone is as effective as morphine for analgesia after cesarean section, and whether it is associated with fewer or more side effects. The results of the study will allow providers to make educated decisions to better care for their patient.

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
May 5, 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yaakov Beilin

Professor of Anesthesiology

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • Elective primary cesarean section
  • Females age 18-40

Exclusion Criteria

  • Emergency cesarean section
  • Anesthetic other than spinal
  • History of chronic pain or pre-op opioid use
  • Allergy to morphine or hydromorphone

Arms & Interventions

Intrathecal morphine

0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections

Intervention: Intrathecal morphine

Intrathecal hydromorphone

50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.

Intervention: Intrathecal hydromorphone

Outcomes

Primary Outcomes

Post Operative Fentanyl PCA Consumption

Time Frame: at 24 hours

Total dose of fentanyl patient controlled analgesia (pca) used in 24 hours post-op.

Secondary Outcomes

  • Patient Satisfaction Score(at 24 hours)
  • Symptom Scale for Two Specific Side Effects of Nausea and Pruritus(up to 24 hours)
  • Time to Initial PCA Use(up to 24 hours)
  • Pain Score(at 24 hours)

Study Sites (1)

Loading locations...

Similar Trials